Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New One-Hour blood test could speed up heart attack diagnosis

NCT ID NCT03507270

Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new one-hour diagnostic algorithm using a protein called FABP to quickly confirm or rule out a type of heart attack called NSTEMI. It involved 20 male patients who arrived at the hospital within 4 hours of chest pain. The goal was to see if measuring FABP levels could help doctors make faster decisions about treatment and hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fatty-acid-binding protein (FABP) diagnostic test
What this could lead to
If successful, this could lead to a faster, more accurate way to diagnose non-ST elevation heart attacks within one hour, helping doctors decide on treatment sooner.
What could go wrong
This is a very small pilot study with only 20 male participants, so results may not apply to women or larger populations. The test's accuracy is still uncertain and needs more research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

May 2017

Finished

Oct 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18-80 years old * Male patients * Acute pain in the chest similar to myocardial infarction with/or without ECG changes * Admission to the hospital within 4 hours from onset of the disease. Exclusion Criteria: * Patients with ACS in the preceding 30 days * Cerebral blood circulation disorder * Recent surgical intervention * Extensive burns of degree 2-3 * Massive wounds and injuries * Percutaneous coronary intervention or cardioversion * Pregnancy or lactation * Malignant tumors of stage 4 * Severe renal insufficiency (GFR\< 30 mL/min)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non ST segment elevation myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute subendocardial myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non ST segment elevation myocardial infarction

Contacts and locations

Locations

  • Cardiology Research Institute, Tomsk NRMC

    Tomsk, 634012, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.